Prolonged QTc Interval: Causes, Risk Factors, and Diagnostic Guidance

Etiology of Prolonged QTc

Prolonged QTc results from either congenital genetic mutations affecting cardiac ion channels or acquired factors such as QT‑prolonging medications, electrolyte abnormalities, structural heart disease, bradycardia, and hypothermia. 1

QT‑prolonging drugs are the leading cause of acquired QTc prolongation in hospitalized patients. 1
Antiarrhythmic agents (e.g., sotalol, dofetilide, ibutilide, amiodarone, procainamide, quinidine, disopyramide) cause torsades de pointes in 1–10 % of treated patients. 2
Fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin) and macrolide antibiotics (especially erythromycin) carry significant QT risk, whereas penicillins and cephalosporins have negligible risk. 1
High‑risk antipsychotics include haloperidol, ziprasidone, iloperidone, amisulpride, thioridazine, and chlorpromazine; other agents such as aripiprazole, clozapine, and lurasidone have minimal QT effects. 1
Among antidepressants, citalopram and escitalopram have the greatest QT impact; sertraline and paroxetine pose minimal risk. 1
Ondansetron and droperidol prolong QTc, while aprepitant and dexamethasone are safer antiemetic alternatives. 1
Methadone and other opioid analgesics require baseline and follow‑up ECG monitoring due to a well‑documented torsades risk. 1, 2
The website crediblemeds.org should be consulted to identify all QT‑prolonging agents before initiating new therapy. 1

Hypokalemia is the single most frequent electrolyte trigger of acquired QT prolongation. 1
Target serum potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L) to mitigate risk. 1, 4
Hypomagnesemia often coexists with hypokalemia, especially in patients on diuretics; correction to serum magnesium > 2.0 mg/dL is recommended. 1
Hypocalcemia also lengthens QTc and should be normalized when present. 1, 4
Diuretic use is a major risk factor because it predisposes to both hypokalemia and hypomagnesemia. 1

Bradycardia (sinus bradycardia or AV block) independently prolongs QT regardless of other contributors. 1, 5
Structural heart disease—including left ventricular dysfunction, hypertrophy, congestive heart failure, and valvular disease—markedly heightens the risk of drug‑induced arrhythmias. 1, 5
Myocardial ischemia can also prolong the QT interval. 5
Hypothermia directly prolongs ventricular repolarization. 1
Renal failure increases drug accumulation and QT‑prolongation risk. 5
Hepatic failure impairs drug metabolism, further elevating QT risk. 5
Malnutrition, often accompanied by electrolyte disturbances, contributes to QT prolongation. 5

cLQTS is caused by autosomal dominant mutations in cardiac ion‑channel genes, most commonly KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3). 1
LQT1 accounts for ≈ 40–50 % of genetically confirmed cases; events are typically triggered by exercise or swimming. 1
LQT2 accounts for ≈ 30–40 % of cases; events are triggered by sudden loud noises (e.g., alarm clocks, doorbells) or emotional stress. 1
LQT3 accounts for ≈ 5–10 % of cases; events occur at rest or during sleep. 1
Approximately 15–20 % of clinically diagnosed cLQTS patients have no identifiable pathogenic variant and are termed “genetically elusive.” 1

Unexplained syncope precipitated by exercise, swimming, or sudden loud noises. 1
Seizure‑like episodes that may represent misdiagnosed cardiac events; consider QTc assessment in refractory epilepsy. 1
Family history of sudden unexplained death before age 40 years. 1, 5
Resuscitated sudden cardiac death. 1
Persistent QTc > 480 ms after discontinuation of all QT‑prolonging drugs and correction of electrolytes. 1

Female sex is the strongest demographic predictor of drug‑induced QT prolongation; women develop longer QT intervals after puberty (≈ 12–14 years of age). 1, 5
Age > 60 years amplifies QT‑prolonging risk from medications and electrolyte disturbances. 1, 5
Drug‑drug interactions that inhibit CYP3A4 metabolism (e.g., ketoconazole, ritonavir) can dramatically elevate QT risk by raising plasma drug concentrations. 2

Repeat the ECG after five drug half‑lives and after electrolyte normalization; a QTc < 450 ms in men or < 460 ms in women indicates acquired LQTS, obviating the need for genetic testing. 1
Acquired LQTS clues: recent initiation of a QT‑prolonging drug, presence of electrolyte disturbances, QTc normalization after drug cessation and electrolyte correction, and presentation at older age (> 50 years). 1
Congenital LQTS clues: genotype‑specific triggers (exercise for LQT1, loud noises for LQT2), family history of early sudden death, persistent QTc > 480 ms after eliminating reversible causes, characteristic T‑wave morphologies, and presentation at a young age. 1

Do not overlook “innocuous” QT‑prolonging medications such as macrolide antibiotics, fluoroquinolones, common antidepressants, and proton‑pump inhibitors. 1
Do not assume all drugs within a class have equal QT risk; citalopram/escitalopram carry the highest SSRI‑related QT risk, whereas sertraline and paroxetine are essentially negligible. 1
Do not ignore electrolyte monitoring in patients on diuretics; hypokalemia and hypomagnesemia are the most common contributors to acquired LQTS. 1
Do not add multiple QT‑prolonging agents without checking for interactions on crediblemeds.org. 1
Do not diagnose congenital LQTS without first excluding all acquired causes, especially in patients > 50 years old. 1